Volume 12, Issue 8, Pages (August 2011)

Slides:

Advertisements

Similar presentations

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Fever of unknown origin and cancer: a population-based study

Volume 370, Issue 9586, Pages (August 2007)

Volume 367, Issue 9517, Pages (April 2006)

Volume 357, Issue 9257, Pages (March 2001)

Volume 376, Issue 9747, Pages (October 2010)

Volume 11, Issue 4, Pages (April 2012)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 378, Issue 9785, Pages (July 2011)

Volume 376, Issue 9734, Pages (July 2010)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 5, Issue 4, Pages (April 2006)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 16, Issue 13, Pages (October 2015)

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 366, Issue 9482, Pages (July 2005)

Volume 13, Issue 3, Pages (March 2012)

Volume 392, Issue 10145, Pages (August 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 388, Issue 10052, Pages (October 2016)

Volume 1, Issue 3, Pages (August 2014)

Volume 373, Issue 9677, Pages (May 2009)

Volume 376, Issue 9757, Pages (December 2010)

Aspirin in the prevention of cancer – Author's reply

Volume 385, Issue 9966, Pages (January 2015)

Volume 9, Issue 9, Pages (September 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 383, Issue 9926, Pages (April 2014)

Volume 378, Issue 9786, Pages (July 2011)

Volume 9, Issue 10, Pages (October 2008)

Volume 12, Issue 7, Pages (July 2011)

Volume 375, Issue 9732, Pages (June 2010)

Volume 4, Issue 6, Pages (June 2017)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

Volume 378, Issue 9785, Pages (July 2011)

Volume 9, Issue 9, Pages (September 2008)

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 372, Issue 9647, Pages (October 2008)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 18, Issue 8, Pages (August 2017)

Volume 378, Issue 9786, Pages (July 2011)

Volume 381, Issue 9880, Pages (May 2013)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile):

Volume 5, Issue 4, Pages (April 2018)

Volume 19, Issue 10, Pages (October 2018)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort.

Volume 381, Issue 9878, Pages (May 2013)

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 18, Issue 10, Pages (October 2017)

Volume 12, Issue 8, Pages (August 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 372, Issue 9632, Pages (July 2008)

Volume 20, Issue 5, Pages (May 2019)

Volume 373, Issue 9680, Pages (June 2009)

Volume 371, Issue 9611, Pages (February 2008)

Volume 6, Issue 7, Pages (July 2019)

Presentation transcript:

Volume 12, Issue 8, Pages 743-752 (August 2011) Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial Prof Gareth J Morgan, MD, Prof J Anthony Child, MD, Prof Walter M Gregory, PhD, Alex J Szubert, MSc, Kim Cocks, MSc, Sue E Bell, DPhil, Nuria Navarro-Coy, MPhil, Mark T Drayson, MD, Roger G Owen, MD, Sylvia Feyler, MD, A John Ashcroft, MD, Fiona M Ross, DPhil, Jennifer Byrne, MD, Huw Roddie, MD, Claudius Rudin, MD, Gordon Cook, MD, Prof Graham H Jackson, MD, Ping Wu, MSc, Faith E Davies, MD The Lancet Oncology Volume 12, Issue 8, Pages 743-752 (August 2011) DOI: 10.1016/S1470-2045(11)70157-7 Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The complete trial protocol is provided in Morgan and colleagues.12 CVAD=cyclophosphamide, vincristine, doxorubicin, and dexamethasone. CTD=cyclophosphamide, thalidomide, and dexamethasone. MP=melphalan and prednisolone. CTDa=attenuated CTD. The Lancet Oncology 2011 12, 743-752DOI: (10.1016/S1470-2045(11)70157-7) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 2 Time to first skeletal-related event overall (A), in patients with bone lesions at baseline (B), and in patients without bone lesions at baseline (C) HR=hazard ratio. *Cox p value. The Lancet Oncology 2011 12, 743-752DOI: (10.1016/S1470-2045(11)70157-7) Copyright © 2011 Elsevier Ltd Terms and Conditions

Figure 3 Proportion of patients with an on-study skeletal-related event overall (A), with bone lesions at baseline (B), and without bone lesions at baseline (C) The Lancet Oncology 2011 12, 743-752DOI: (10.1016/S1470-2045(11)70157-7) Copyright © 2011 Elsevier Ltd Terms and Conditions